Merck & Co., Inc., Kenilworth, NJ, USA.
Beckman Coulter Life Sciences, San Jose, CA, USA.
SLAS Discov. 2021 Feb;26(2):168-191. doi: 10.1177/2472555220980696.
For nearly two decades mass spectrometry has been used as a label-free, direct-detection method for both functional and affinity-based screening of a wide range of therapeutically relevant target classes. Here, we present an overview of several established and emerging mass spectrometry platforms and summarize the unique strengths and performance characteristics of each as they apply to high-throughput screening. Multiple examples from the recent literature are highlighted in order to illustrate the power of each individual technique, with special emphasis given to cases where the use of mass spectrometry was found to be differentiating when compared with other detection formats. Indeed, as many of these examples will demonstrate, the inherent strengths of mass spectrometry-sensitivity, specificity, wide dynamic range, and amenability to complex matrices-can be leveraged to enhance the discriminating power and physiological relevance of assays included in screening cascades. It is our hope that this review will serve as a useful guide to readers of all backgrounds and experience levels on the applicability and benefits of mass spectrometry in the search for hits, leads, and, ultimately, drugs.
近二十年来,质谱已被广泛应用于功能和基于亲和力的筛选,作为一种无标记、直接检测的方法,用于治疗相关的各种靶标类。在这里,我们概述了几种已建立和新兴的质谱平台,并总结了它们各自在高通量筛选中的独特优势和性能特点。本文强调了来自近期文献的多个实例,以说明每种技术的强大功能,特别关注在与其他检测形式相比使用质谱时发现具有区分能力的情况。事实上,正如许多实例所证明的那样,质谱的固有优势——灵敏度、特异性、宽动态范围和适用于复杂基质——可用于增强筛选级联中测定的区分能力和生理相关性。我们希望本综述能为所有背景和经验水平的读者提供一个有用的指南,了解质谱在寻找命中物、先导化合物以及最终药物方面的适用性和好处。